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Low ADAMTS13 activity is associated with an increased risk of cardiovascular disease, which is 
generally attributed to its proteolytic effects on Von Willebrand factor (VWF). Cardiovascular health is 
an important determinant of cognitive decline, but the association of either VWF or ADAMTS13 with 
risk of dementia is unknown. Between 1997–2002, we measured VWF antigen and ADAMTS13 activity 
in 6055 participants of the population-based Rotterdam Study (mean age 69.3 years, 57.2% women). 
At baseline, 85 participants had dementia, and during 15 years of follow-up 821 developed dementia. 
Higher VWF was associated with prevalence and risk of dementia, unaffected by concurrent ADAMTS13 
activity, but estimates strongly attenuated over time and were no longer statistically significant at 4 
years of follow-up (relative risks [95% CI] per standard deviation increase– cross-sectional: 1.37 [1.06–
1.77], and longitudinal: 1.05 [0.97–1.14]). In contrast, low ADAMTS13 was associated with increased 
risk of dementia throughout follow-up (hazard ratio per SD decrease– 1.16 [1.06–1.28]), which alike 
for ischaemic stroke, was modified by the presence of diabetes (P-interaction = 0.003). In conclusion, 
higher VWF and low ADAMTS13 activity are associated with increased risk of dementia, but differences 
in time-course and lack of synergistic effects may indicate in part independent underlying mechanisms.
Von Willebrand factor (VWF) is a large multimeric glycoprotein with critical functions in haemostasis. 
Deficiency or dysfunction of VWF, known as Von Willebrand disease, can cause prolonged or excessive bleeding1, 
whereas high levels of VWF antigen have been associated with increased risk of cardiovascular disease2. In vivo 
effects of VWF largely depend on the proteolytic activity of ADAMTS13 (A Disintegrin And Metalloproteinase 
with a ThromboSpondin type 1 motif, member 13). ADAMTS13 cleaves large, haemostatically highly reactive 
VWF multimers into smaller, less active multimers. Consequently, high VWF may lead to a hypercoagulable 
state in particular when ADAMTS13 activity is low, and a combined measure of VWF and ADAMTS13 could 
thus more accurately capture the biological activity of VWF3. We have previously shown that low activity of 
ADAMTS13 itself is associated with increased risk of cardiovascular disease4–8, while the combination of VWF 
and ADAMTS13 appears indeed more strongly associated with stroke risk than what would be expected on the 
basis of the individual measurements5.
Vascular disease and thrombosis play an important role in the aetiology of dementia, including Alzheimer’s 
disease9. Accordingly, a recent meta-analysis of cross-sectional studies concluded that VWF antigen levels are 
higher in patients with dementia than in controls10. However, of two studies that assessed the risk of demen-
tia by VWF11,12, neither found baseline VWF antigen levels associated with dementia risk after 4 and 17 years 
of follow-up, respectively, albeit the latter was hampered by substantial attrition (50%) and lack of cognitive 
screening at baseline. Apart from methodological considerations, release of VWF from damaged endothelial 
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cells in later stages of cognitive impairment may explain why profound cross-sectional associations do not extend 
to longer term follow-up. However, the time-course of the association between VWF and dementia remains 
unknown, and although ADAMTS13 could aid in disentangling haemostatic effects from associations marking 
endothelial damage, no published studies about VWF and dementia took into account concurrent ADAMTS13 
activity.
While VWF is the only known substrate for ADAMTS13, several studies suggest that ADAMTS13 might 
have functions beyond VWF cleavage. Suggested roles include inflammation, angiogenesis, and extracellular 
matrix integrity13, each of which have been implicated also in the aetiology of dementia14–16. A versatile role of 
ADAMTS13 was further suggested, when we recently showed that high activity of ADAMTS13 relates to a higher 
risk of diabetes in the general population17. The underlying mechanisms remain elusive, but these studies jointly 
highlight the need for investigation of ADAMTS13 in the context of, as well as beyond its proteolytic activity of 
VWF.
We aimed to determine the cross-sectional and long-term associations of VWF and ADAMTS13 with cogni-
tive decline and dementia risk in a population-based study. We investigated independent and synergistic effects 
of VWF and ADAMTS13, and explored these associations in the context of prior studies linking ADAMTS13 to 
diabetes, angiogenesis, and extracellular matrix integrity.
Methods
This study is part of the Rotterdam Study, a large ongoing population-based cohort study in the Netherlands, with 
an initial study population of 7,983 participants aged ≥ 55 years from the Ommoord area, a suburb of Rotterdam. 
In 2000, the cohort was expanded with an additional 3011 participants who moved into the study area or reached 
age 55. The Rotterdam Study methods have been described previously18. Briefly, participants were interviewed 
at home and subsequently examined at the research centre for baseline assessment from 1990 to 1993 (baseline 
cohort) and 2000 to 2002 (expansion cohort), with follow-up examinations every 4 years. Citrated plasma sam-
ples were collected at the third visit of the original cohort (1997–1999), and the first visit of the expansion cohort 
(2000–2002), which are the baseline of the current study. Of 9,030 surviving participants at the time, 7,510 par-
ticipated in this examination cycle, of whom 6,735 visited the study centre. Of these, 43 had insufficient cognitive 
screening to determine dementia status.
Ethical approval and data availability. The Rotterdam Study has been approved by the medical ethics 
committee according to the Population Study Act Rotterdam Study, executed by the Ministry of Health, Welfare 
and Sports of the Netherlands. Written informed consent was obtained from all participants. Rotterdam Study 
data can be made available to interested researchers upon request. Requests can be directed to data manager 
Frank J.A. van Rooij (f.vanrooij@erasmusmc.nl). We are unable to place data in a public repository due to legal 
and ethical restraints. Sharing of individual participant data was not included in the informed consent of the 
study, and there is potential risk of revealing participants’ identities as it is not possible to completely anonymize 
the data. This is of particular concern given the sensitive personal nature of much of the data collected as part of 
the Rotterdam Study.
Measurement of Von Willebrand factor antigen and ADAMTS13 activity. Fasting venous blood 
samples were taken at the research centre, and citrated plasma was stored at –80 °C. We determined VWF anti-
gen with an in-house enzyme-linked immunosorbent assay using polyclonal rabbit antihuman VWF antibodies 
(DakoCytomation, Glostrop, Denmark) for catching and tagging. The intra-assay coefficient of variation was 
5.8% and the inter-assay coefficient of variation was 7.8%. We measured ADAMTS13 activity using a kinetic 
assay based on the fluorescence resonance energy transfer substrate VWF73 (FRETSVWF73) assay19. This assay 
uses a peptide containing the ADAMTS13 cleavage site of VWF, and thus captures variation in the VWF cleavage 
rate determined by ADAMTS13 levels and structure. Plasma samples were measured against a reference curve of 
serial dilutions of normal human plasma defined to have an ADAMTS13 activity of 1 IU/mL, and we expressed 
ADAMTS13 activity as a percentage of this. Ten percent of the samples were retested and all were within 25% 
variation. From these measurements, we also calculated the ratio between ADAMTS13 activity and VWF antigen 
levels.
Cognitive function assessment and dementia screening. Participants underwent detailed tests to 
determine cognitive function, comprising the Stroop test (error adjusted time in seconds taken for completing a 
reading/colour naming interference task), the letter-digit substitution task (number of correct digits in 1 minute), 
and the verbal fluency test (number of animal species within 1 minute)20. Cognitive function was assessed at 
baseline (i.e. time of blood sampling) and at three subsequent follow-up examinations (after a mean follow-up of 
4.4 (SD 0.6), 10.8 (SD 0.6), and 15.4 (SD 0.7) years, respectively). To obtain a composite measure of test perfor-
mance, we calculated the G-factor, which explained approximately 61% of variance in cognitive test scores at each 
examination round in our population. For each participant, Z-scores were calculated for each test separately, by 
dividing the difference between individual test score and population mean by the population standard deviation.
Participants were screened for dementia at baseline and subsequent centre visits21. Those with a Mini-Mental 
State Examination score < 26 or Geriatric Mental Schedule score > 0 underwent further investigation and 
informant interview, including the Cambridge Examination for Mental Disorders of the Elderly. In addition, the 
entire cohort was under continuous surveillance for dementia through electronic linkage of the study database 
with medical records from general practitioners and the regional institute for outpatient mental health care. A 
consensus panel led by a consultant neurologist established the final diagnosis according to standard criteria for 
dementia (DSM-III-R) and Alzheimer’s disease (NINCDS–ADRDA). Within this period, participants were cen-
sored at date of dementia diagnosis, death, loss to follow-up, or 1st January 2015, whichever came first.
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Other measurements. We assessed smoking status (i.e. current, former, never) and use of antihypertensive, 
lipid-lowering, glucose lowering, and antithrombotic (i.e. coumarine derivatives or platelet inhibitors) medication 
at baseline by interview. Systolic and diastolic blood pressures were measured with a random-zero sphygmoma-
nometer. Fasting serum lipid levels, C-reactive protein (CRP) and fibrinogen were measured at baseline. Diabetes, 
prediabetes and normoglycaemia were defined according to WHO guidelines22. APOE genotype was determined 
using polymerase chain reaction on coded DNA samples (baseline cohort), and using a bi-allelic TaqMan assay 
(rs7412 and rs429358; expansion cohort). ABO blood group antigen phenotypes were reconstructed by haplotype 
analysis of 3 single nucleotide polymorphisms (rs8176749, rs8176704, and rs505922), and classified into O and 
non-O. We determined history of stroke and myocardial infarction by interview, consultation of medical records, 
and abnormalities on electrocardiography.
Measurement of other blood markers. In a subset of 1075 non-demented participants, we measured 
at baseline 150 plasma markers via multiplex immunoassay on human multianalyte profiles in the fasting blood 
samples collected at baseline (Myriad RBM Inc., Austin TX, USA; http://rbm.myriad.com). Of these, we selected 
markers with an identified role in angiogenesis (i.e. angiopoietin-2 (ANG-2), vascular endothelial growth fac-
tor (VEGF), platelet-derived growth factor (PDGF), transforming growth factors α and β (TGF-α, TGF-β)) or 
related to the extracellular matrix (i.e. matrix metalloproteinases MMP-2, MMP-3, and MMP-9, tissue inhibitor 
of metalloproteinase-1 (TIMP-1), Tenascin-C, connective tissue growth factor (CTGF)), based on suggested roles 
of ADAMTS13 beyond regulation of thrombosis13. The assay did not pass quality control (>20% unmeasurable) 
for TGF-α, TGF-β, MMP-2, MMP-9 and CTGF, leaving 6 markers for analysis (all with measurements in ≥92.4% 
of participants).
Analysis. Because of a right-skewed distribution of VWF and the ADAMTS13:VWF-ratio, we performed a 
natural logarithmic transformation to obtain a roughly normal distribution of the data. We computed Z-scores 
for each individual by dividing the difference between the individual value and the population mean by the pop-
ulation standard deviation.
Missing covariate data (15.0% for ABO blood type, and <5.0% for all other covariables) were imputed using 
5-fold multiple imputation. Distribution of covariates was similar in the imputed versus non-imputed dataset. All 
analyses were adjusted for age, sex, and study subcohort. In a second model we further adjusted for systolic and 
diastolic blood pressure, use of antihypertensive medication, serum total cholesterol, high-density lipoprotein 
(HDL) cholesterol and triglycerides, use of lipid-lowering medication, body mass index, diabetes mellitus, creati-
nine, CRP, fibrinogen, ABO blood type, and use of antithrombotic medication.
We determined the association of VWF and ADAMTS13 with prevalence and incidence of dementia, using 
logistic regression and Cox proportional hazard models, respectively. As the proportional hazard assumption was 
violated for VWF, we also determined associations with dementia risk per year increase in follow-up. We deter-
mined risk of dementia per standard deviation (SD) increase as well as per quartile of VWF, ADAMTS13, and 
their ratio. In view of previously suggested threshold effects of ADAMTS13, we also compared the lowest quartile 
of ADAMTS13 to the highest three quartiles altogether2. We assessed effect modification by (pre-)diabetes, by 
testing for multiplicative interaction in the fully adjusted Cox model. We repeated the analysis after excluding 
participants with prevalent myocardial infarction or stroke, while censoring at time of incident myocardial infarc-
tion or stroke in the fully adjusted model. We performed further sensitivity analyses, 1) for Alzheimer’s disease 
only, 2) stratifying by the mean age of the study population (i.e. 69.3 years), 4) stratifying by sex, and 5) stratifying 
by blood type O versus non-O.
We then determined the association of VWF levels and ADAMTS13 activity with change in scores on cog-
nitive assessment during follow-up, using linear mixed models. We fitted a model (restricted maximum likeli-
hood) to the G-factor of cognitive scores, including age, sex, follow-up time, time*age, VWF/ADAMTS13, and 
time*VWF/ADAMTS13 in the model. We chose a diagonal covariance structure (heterogeneous variance and 
zero correlation between elements) for the random effects, including a random intercept and follow-up time, 
and added other covariates in agreement with the fully adjusted model described above. We repeated the anal-
ysis for all cognitive tests, stratified by diabetic status, and limited to the 1st, 2nd, and 3rd follow-up examination, 
respectively.
Finally, in the subset of participants with immunoassay data, we determined correlations of ADAMTS13 with 
ANG-2, VEGF, PDGF, MMP-3, TIMP-1, and Tenascin-C, using linear regression (of natural log-transformed 
values if so required to obtain normal distributions of the data). Values exceeding ± 3.5 standard deviations from 
the mean were excluded from analysis. We fitted univariable models, and additional models including age, sex, 
and each of the other biomarkers, whilst applying the Benjamini-Hochberg correction for multiple testing.
All analyses were done using SPSS Statistics 21.0 (IBM Corp, Armonk, NY, USA) or R statistical software 3.1.1 
(package ‘nlme’). Alpha level was set at 0.05.
Results
Among 6,692 eligible participants, we could not determine VWF antigen in 380 participants and ADAMTS13 
activity in 628 participants, mainly due to technical reasons or insufficient blood sampling, leaving 6055 (90.5%) 
participants with both measures for analyses. Baseline characteristics of the study population are presented in 
Table 1.
Prevalent dementia. At baseline, 85 participants had dementia, of whom 68 had Alzheimer’s disease. 
Participants with dementia had higher VWF antigen levels and lower ADAMTS13 activity than individuals with-
out dementia (Table 2). Consequently, the ADAMTS13:VWF ratio was also lower in individuals with dementia, 
although adjustment for ADAMTS13 did not change the estimates for VWF, and ADAMTS13 did not modify the 
www.nature.com/scientificreports/
4SCIENTIfIC RepoRts |  (2018) 8:5474  | DOI:10.1038/s41598-018-23865-7
association of VWF with dementia (Table 2; P-interaction = 0.93). Associations of VWF and ADAMTS13 with 
dementia were mildly attenuated for Alzheimer’s disease only, and broadly unaltered by excluding participants 
with cardiovascular disease (Supplementary Table S1).
Longitudinal assessment. Of 5,970 non-demented participants at baseline, 821 participants were diag-
nosed with dementia during a mean follow-up of 11.6 years (follow-up was complete for 97.5% of potential per-
son years). Of all dementia diagnoses, 671 were due to Alzheimer’s disease, and 154 were preceded by myocardial 
Age (years) 69.3 (±8.2)
Female sex 3,461 (57.2)
Systolic blood pressure (mmHg) 143 (±21)
Diastolic blood pressure (mmHg) 77 (±11)
Antihypertensive medication 2,017 (35.0)
Pre-diabetes 1,663 (28.1)
Diabetes 744 (12.6)
Serum cholesterol (mmol/L) 5.82 (±0.98)
Serum HDL cholesterol (mmol/L) 1.39 (±0.39)
Serum triglycerides (mmol/L; median, IQR) 1.35 (1.03–1.81)




Creatinine (mg/dL) 0.89 (±0.21)
Body-mass index (kg/m2) 26.9 (±4.0)
History of cardiovascular disease 283 (4.7)
Anti-thrombotic medication 1,135 (18.7)
APOE genotype
 3/3 3,389 (58.1)
ε2/2 or ε2/3 821 (14.1)
 ε2/4 or ε3/4, ε4/4 1,627 (27.9)
Von Willebrand factor (IU/mL; median, IQR) 1.20 (0.93–1.60)
ADAMTS13 (%) 91.5 (±17.7)
Fibrinogen (g/L; median, IQR) 3.8 (3.3–4.4)
C-reactive protein (mg/mL; median, IQR) 1.8 (0.7–3.7)
Blood type O 2348 (45.6)
Table 1. Baseline characteristics of the 6,055 participants. Data are presented as frequency (%) for categorical, 
and mean ± standard deviation for continuous variables, unless indicated otherwise; IQR = interquartile range.
All-cause dementia (Model I)
P-value
All-cause dementia (Model II)
P-valueNo (n = 5,970) Yes (n = 85) No (n = 5,970) Yes (n = 85)
VWF:Ag
Geometric mean (95% CI) 1.22 (1.20–1.23) 1.34 (1.23–1.46) 0.021 1.23 (1.20–1.26) 1.36 (1.26–1.48) 0.013
OR (95% CI) per SD increase 1.29 (1.04–1.62) 0.023 1.37 (1.06–1.77) 0.017
ADAMTS13 activity
Mean (95% CI) 91.2 (90.7–91.6) 86.1 (82.5–89.7) 0.007 91.2 (90.1–92.4) 86.9 (83.2–90.6) 0.015
OR (95% CI) per SD decrease 1.28 (1.01–1.64) 0.046 1.25 (0.95–1.63) 0.107
ADAMTS13:VWF ratio
Geometric mean (95% CI) 73.5 (72.6–74.3) 61.9 (56.3–68.2) 0.001 72.5 (70.5–74.7) 61.6 (56.1–67.6) 0.0004
OR (95% CI) per SD decrease 1.39 (1.12–1.72) 0.003 1.44 (1.13–1.85) 0.004
Table 2. Von Willebrand factor (VWF) and ADAMTS13 at baseline in relation to the prevalence of dementia. 
n = number of participants; SD = standard deviation; OR = odds ratio from logistic regression model; 
CI = confidence interval. Geometric means facilitate a comparison of normalized results, as is the case for 
the not normally distributed VWF and the ADAMTS13:VWF ratio. Model I: adjusted for age, sex, study 
subcohort. Model II: model I with additional adjustment for smoking, systolic and diastolic blood pressure, 
antihypertensive medication, diabetes, serum cholesterol, high density lipoprotein cholesterol and triglycerides, 
lipid-lowering medication, body mass index, creatinine, antithrombotic medication, fibrinogen, C-reactive 
protein, ABO blood type, and APOE genotype.
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infarction or a stroke. At baseline, 5,844/5,970 (97.9%) participants underwent extensive cognitive assessment, of 
whom 4,582 (78.4%) underwent at least 2 assessments, and 2,934 (50.2%) attended at least three examinations.
VWF and cognitive decline/ incident dementia. Overall, VWF antigen levels were not associated with 
risk of dementia (adjusted HR per SD increase: 1.05, 0.97–1.14). VWF levels were, however, associated with 
short-term risk of dementia, but these associations attenuated over time and were no longer statistically signifi-
cant beyond 4 years of follow-up (Fig. 1A; for a full table see Supplementary Table S2). Similarly, associations of 
VWF with cognitive test performance at baseline extended to the first re-examination at 4.4 years, but not thereaf-
ter (Fig. 1B; for results per quartile of VWF see Supplementary Table S3). The associations of VWF with cognitive 
decline and risk of dementia were not affected by concurrent ADAMTS13 activity (P-value for the interaction 
VWF*ADAMTS13 = 0.58 for all-cause dementia and and 0.85 the G-factor).
ADAMTS13 and cognitive decline/ incident dementia. Low ADAMTS13 activity was associated with 
an increased risk of dementia (Table 3), with similar effect estimates throughout follow-up. The association was 
modified by the presence of impaired fasting glucose or diabetes (P-interaction = 0.003), such that low activity of 
ADAMTS13 related to higher risk of dementia primarily in non-diabetics, but not in those with (pre-)diabetes 
(Table 3). This opposite direction of effect was similar for impaired fasting glucose and diabetes (Supplementary 
Table S4), and unaffected by excluding individuals using antidiabetic medication. Risk estimates of ADAMTS13 
itself were consistently stronger than those of the ADAMTS13:VWF ratio (Supplementary Table S5), and in con-
trast to ADAMTS13 there was no interaction between (pre-)diabetes and VWF on the risk of dementia (P-value 
for the VWF*(pre-)diabetes interaction = 0.99).
ADAMTS13 was associated with more rapid decline in cognitive test performance during 15 years of 
follow-up (Fig. 2), which was again most profound in individuals without diabetes (Supplementary Table S6). The 
ADAMTS13:VWF ratio was also associated with change in cognitive test performance, with similar effect esti-
mates, except for a somewhat stronger association with performance on the Stroop test (Supplementary Table S7). 
Associations were broadly unaltered after excluding all participants who developed dementia during follow-up 
(Supplementary Table S8).
Sensitivity analyses. In further sensitivity analyses, associations of VWF and ADAMTS13 with demen-
tia were similar for Alzheimer’s disease only, and unaffected by excluding those with prevalent cardiovascular 
disease and censoring participants at time of myocardial infarction or stroke during follow-up (Supplementary 
Figure S1). We found no evidence of effect modification by age at blood sampling, sex, or ABO blood type 
(Supplementary Figure S1; all P-values for interaction ≥ 0.15).
ADAMTS13 and immunoassay markers. Among a random subset of 1075 participants with immu-
noassay biomarker measurements, lower ADAMTS13 activity was significantly associated with higher levels 
of VEGF, MMP-3, and Tenascin-C, but not ANG-2 and PDGF (Table 4). The univariable association between 
MMP-3 and ADAMTS13 attenuated after adjustment for age and sex, but differed substantially by concurrent 
Figure 1. Von Willebrand factor (VWF) in relation to risk of dementia and cognitive performance over time. 
(A) Cross-sectional estimates at baseline (odds ratio from logistic regression) are followed by hazard ratios for 
the risk of incident dementia in longitudinal analyses including one extra year of follow-up from baseline per 
presented figure (Cox regression). Results are from the fully adjusted model. HR = hazard ratio; CI = confidence 
interval; SD = standard deviation. (B) Results reflect the betas per standard deviation increase for baseline 
VWF and the VWF*follow-up time interaction (expressed per 10 years follow-up) from a fully adjusted linear 
mixed model including all four examinations, and restricting analyses to the first two or three assessments, 
respectively. T0 = baseline; T1 = first follow-up examination after 4.4 years; T2 = second follow-up examination 
after 10.8 years; T3 = third follow-up examination after 15.4 years. Lower scores reflect worse performance for 
all tests. Presented cross-sectional estimates from the model including all examinations were robust in the time-
restricted models.
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levels of TIMP-1 (P-value for interaction = 0.01), such that associations were strongest in the presence of high 
TIMP-1. A similar interaction was seen between Tenascin-C and TIMP-1 (P-value for interaction = 0.05).
Discussion
In this large population-based study, we found that higher VWF antigen levels are associated with prevalence and 
short-term, but not long-term risk of dementia. Low ADAMTS13 activity is associated with dementia risk during 
prolonged follow-up, with data suggesting an interactive mechanisms between ADAMTS13 and diabetes in the 
development of dementia. We did not observe synergistic effects of VWF and ADAMTS13 activity, which might 
indeed indicate in part independent underlying mechanisms.
ADAMTS13 
activity
Overall study population Free of (pre-)diabetes With (pre-)diabetes
ndem/Ntot HR (95% CI) ndem/Ntot HR (95% CI) ndem/Ntot HR (95% CI)
Per quartile
  Q1<80.6% 239/1,492 1.16 (0.94–1.43) 190/1081 1.51 (1.16–1.95) 49/401 0.64 (0.43–0.95)
  Q280.6–91.2% 210/1,493 1.00 (0.82–1.23) 158/1088 1.22 (0.94–1.57) 51/389 0.67 (0.46–0.97)
  Q391.2–101.9% 191/1,493 0.85 (0.69–1.04) 133/1095 0.90 (0.69–1.17) 58/391 0.77 (0.54–1.10)
  Q4>101.9% 181/1,492 reference 106/995 reference 74/482 reference
Q1 versus Q2–4 1.23 (1.05–1.44) 1.44 (1.20–1.73) 0.81 (0.58–1.13)
Per SD decrease 821/5,970 1.06 (0.98–1.15) 587/4259 1.16 (1.06–1.28) 232/1663 0.90 (0.79–1.03)
Table 3. Baseline ADAMTS13 in relation to the risk of dementia in the overall population, and stratified by 
(pre-)diabetic status. HR = hazard ratio from Cox proportional hazard regression; CI = confidence interval; 
ndem = number of dementia cases and Ntot = number of individuals in group, presented for non-imputed data 
(missing diabetes status, n = 48). Model adjusted for age, sex, study subcohort, smoking, systolic and diastolic 
blood pressure, antihypertensive medication, serum cholesterol, HDL cholesterol and triglycerides, lipid-
lowering medication, body mass index, (pre-)diabetes (if applicable), creatinine, antithrombotic medication, 
CRP, fibrinogen, and APOE genotype.
Figure 2. ADAMTS13 activity and change in cognitive test scores during four consecutive examination 
rounds. Change in cognitive performance per 10 years of follow-up, expressed per quartile of ADAMTS13 
relative to the highest quartile, and comparing low versus normal ADAMTS13 activity. Lower scores reflect 
worse performance for all tests. Model adjusted for age, sex, smoking, systolic and diastolic blood pressure, 
antihypertensive medication, serum cholesterol, HDL cholesterol and triglycerides, lipid-lowering medication, 
body mass index, diabetes, creatinine, antithrombotic medication, CRP, fibrinogen, ABO blood type, and APOE 
genotype.
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The cross-sectional association between VWF and dementia in our study is in line with a recent meta-analysis, 
which reported similar (standardised) differences in VWF levels between individuals with all-cause dementia and 
controls10. However, we found associations to rapidly attenuate over the first few years of follow-up, explaining 
why two prior longitudinal studies did not find a significant association between VWF and risk of dementia 
after 4 and 17 years of follow-up, respectively11,12. The crucial role of time in this association could indicate high 
variability in VWF levels, either physiologically or induced by disease processes or treatment. Levels of VWF in 
the bloodstream may increase exponentially during the course of disease due to increasing severity of endothelial 
injury, and the biological effect of VWF may also vary with physiological changes in advanced stages of disease, 
such as wall shear stress23,24. This physiological variability could be investigated in future studies by incorpo-
ration of multiple measurements of VWF over time, which will prove important to determine to which extent 
prior associations of VWF with (subclinical) disease in fact reflect physiological activity of VWF, or are due to 
endothelial injury.
VWF has been associated with markers of cerebral small-vessel disease that are known risk factors for demen-
tia25,26, including white matter hyperintensities on MRI and microhaemorrhages co-localised with beta-amyloid 
deposits27,28. As high VWF increases the risk of ischaemic stroke29, cerebral ischaemia could further link VWF to 
cognitive decline via (covert) brain infarcts or cortical micro-infarcts.
Such effects might be reduced in individuals with blood type O30, due to accelerated clearance and thus 25% 
lower levels of VWF31,32, although we did not find differential effects of VWF across blood type in our study. 
Beyond its direct effects, the function of VWF as a carrier protein for coagulation factor VIII (FVIII), thereby pro-
longing its half-life 10-fold33, might in part explain recently reported cognitive impairment with higher FVIII30. 
Finally, in vitro study suggests that inflammatory cytokines increase release and inhibit cleavage of VWF34, which 
might link inflammatory and ischaemic pathways in the pathogenesis of Alzheimer’s disease14. Future studies 
linking measurements of VWF to (longitudinal) magnetic resonance neuroimaging may further unravel these 
potential mechanisms.
In contrast to findings for VWF antigen, low ADAMTS13 activity was associated with cognitive decline and 
dementia risk throughout the 15-year follow-up in individuals without (pre-)diabetes. In line with reports of 
myocardial infarction and ischaemic stroke5,8, we observed increased risks only in the lower range of ADAMTS13, 
supporting a threshold effect in ADAMTS13 activity2. Nevertheless, the lower range of activity in the community 
is generally sufficient to maintain the equilibrium of VWF multimer formation and degradation35,36. Along with 
the effect estimates for ADAMTS13 generally exceeding those of the ADAMTS13:VWF ratio, this renders it 
unlikely that proteolytic effects of ADAMTS13 on VWF alone are accountable for the association of ADAMTS13 
with dementia. Yet, most studies about ADAMTS13 have focused on its relationship with VWF or role in throm-
botic thrombocytopenic purpura, and limited data are available to corroborate other pathways. Preliminary 
evidence suggests a role of ADAMTS13 in (downregulation of) inflammation13,37, regulation of angiogenesis13, 
and degradation of extracellular matrix13, which have also been described in dementia14–16. In mice, deficiency 
of ADAMTS13 enhances inflammation and plaque formation38,39, aggravates consequences of cerebral ischae-
mia40–42, and appears to regulate blood-brain barrier permeability43, possibly by controlling vascular remodeling 
via VEGF, ANG-2, and galectin-3 related pathways42,43. While these processes in mice often appear dependent 
on VWF or are observed in ADAMTS-/- mice, the levels required may be limited, and thus generally abundant 
in the general population. In exploratory analyses, we found associations of ADAMTS13 activity with levels of 
VEGF, MMP-3, Tenascin-C, and TIMP-1, which might indeed indicate involvement in vascular remodelling, and 
in any case encourage further study of ADAMTS13 in relation to vascular (brain) disease and neurodegeneration.
Our findings suggest that diabetes pathophysiology, rather than antidiabetic medication, modifies the asso-
ciation between ADAMTS13 and dementia risk. These analyses were prompted by our recent study in which we 
found increased risks of diabetes with higher ADAMTS13 activity17. Although the mechanisms underlying these 
observations are unknown, it is conceivable that ADAMTS13 has other, yet unidentified proteolytic activity, 





Model II – low TIMP-1†
β, 95% CI
Model II – high TIMP-1†
β, 95% CI
ANG-2 0.01 (−1.25; 1.27) 0.72 (−0.62; 2.06) n/a n/a
PDGF 0.64 (−0.41; 1.68) 0.14 (−0.90; 1.19) n/a n/a
VEGF −1.66 (−3.07; −0.25)* −1.83 (−3.33; −0.34)* n/a n/a
MMP-3 −4.03 (−5.05; −3.00)*† −1.37 (−2.64; −0.10)† 0.31 (−1.55; 2.17) −2.93 (−4.69; −1.17)*
Tenascin-C −1.74 (−2.78; −0.70)*† −1.42 (−2.46; −0.37)*† −0.68 (−2.16; 0.81) −2.09 (−3.57; −0.61)*
TIMP-1 −1.31 (−2.47; −0.14)*† 1.40 (0.11; 2.69)† n/a n/a
Table 4. ADAMTS13 and selected markers of angiogenesis and extracellular matrix integrity. 
ANG-2 = angiopoietin-2; PDGF = platelet-derived growth factor; VEGF = vascular endothelial growth factor; 
MMP-3 = matrix metalloproteinase-3; TIMP-1 = tissue inhibitor of metalloproteinases-1. Values represent 
change in ADAMTS13 activity per standard deviation increase in the specific marker. Model I: univariable 
linear regression. Model II: linear regression adjusted for age, sex, and all other biomarkers. *Statistically 
significant at 0.05 level after correction for multiple testing. †The univariable association between MMP-3 
and ADAMTS13 largely attenuated after adjustment for age and sex. There was interaction of MMP-3 and 
Tenascin-C with TIMP-1 on the association with ADAMTS13 (p-values for interaction of 0.01 and 0.05, 
respectively, in the adjusted model); these associations are consequently presented separately for low (<median) 
and high (≥median) TIMP-1.
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would expect that the pathological mechanism underlying this interaction shows similarly in the association of 
ADAMTS13 with related disease outcomes. A previous report of the Rotterdam Study has described an increased 
risk of ischaemic stroke with low ADAMTS13 activity5, but the link between ADAMTS13 and diabetes had not 
yet emerged at the time. Exploring these data further in a post-hoc analysis, we now observed patterns in the 
association between ADAMTS13 and risk of ischaemic stroke, similar to those with dementia in the current study 
(HR [95% CI] per SD decrease in ADAMTS13 for risk of ischaemic stroke in those free of (pre-)diabetes: 1.19 
[1.04–1.36], versus in those with (pre-)diabetes: 0.94 [0.79–1.11]). This points towards a vascular disease related 
interactive mechanism, in which ADAMTS13 has a common role across diseases outcomes. While we encourage 
attempts for replication of our findings in other populations, we believe that current insight warrants serum glu-
cose and diabetes history to be taken into account in future study of ADAMTS13.
Although we believe our results are reliable, there are several limitations. First, despite rigorous adjustment for 
known determinants of VWF and ADAMTS13, residual confounding may still exist, in particular with respect to 
other factors involved in hemostasis, diabetes, or possibly angiogenesis and extracellular matrix stability. Second, 
although follow-up for dementia was near-complete, attrition for repeated detailed cognitive assessment was sub-
stantial. Third, the association between ADAMTS13 and diabetes was first described in the same cohort as drawn 
from in the present analyses, and (large-scale) replication is warranted. Fourth, the Rotterdam Study population 
is predominantly of Caucasian descent, and levels and effects of ADAMTS13 might differ across ethnicities.
In conclusion, higher VWF and low ADAMTS13 activity are associated with accelerated cognitive decline 
and increased risk of dementia. However, associations with VWF are restricted to short-term risks, and do not 
display synergistic effects with ADAMTS13 on dementia risk. The impact of diabetes on the effect of ADAMTS13 
on dementia (as well as ischaemic stroke), further emphasises the need to unravel the biological function of 
ADAMTS13.
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